Formation Bio
PrivateLast Round
Series D
Jun 26, 2024
Est. Valuation
$1.8B
Total Funding Raised
$713.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Formation Bio is a biotechnology company that operates an AI-native drug development platform to acquire, in-license, and accelerate the development of clinical-stage pharmaceutical assets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Formation Bio Comparables
Compare Formation Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Owkin | 77% | |
| Insilico Medicine | 73% | |
| Eli Lilly and Company | 73% |
For institutional investors. Book with your work email.
Formation Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 26, 2024 | ||||
| Series C | Sep 30, 2021 | ||||
| Series B | Oct 15, 2018 | ||||
| Series B | Oct 1, 2018 | ||||
| Series A | Nov 16, 2017 | ||||
Seed | Jul 6, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Formation Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series D |
| S32 | Series C |
| Maveron | Series A, Series B, Seed |
| SV Angel | Series D |
| Founder Collective | Series A, Series B, Seed |
| Thrive Capital | Series C, Series A, Series D, Series B |
| Streamlined Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 91% MoM, reaching 25.9K.
- Apr 2, 2025
Former Pfizer CSO Mikael Dolsten joins as advisor.
For institutional investors. Book with your work email.
Formation Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Formation Bio's valuation, stock price, and market status.
Is Formation Bio a public or private company?
Formation Bio is a private company.
What is the current stock price of Formation Bio?
Formation Bio is a private company, so its shares have no public market price. Caplight tracks Formation Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Formation Bio worth (valuation)?
Formation Bio's valuation is estimated at $1.8B based on funding round data.
Can I buy Formation Bio stock?
Formation Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Formation Bio's last funding round?
Formation Bio's most recent funding round was Series D on June 26, 2024.
Who are the main investors in Formation Bio?
Key investors in Formation Bio include Andreessen Horowitz, Thrive Capital, Sequoia Capital.
Will Formation Bio IPO soon?
No public IPO plans have been announced for Formation Bio.
How can I track Formation Bio secondary market activity?
Caplight tracks bids, offers, and trades in Formation Bio's shares on secondary markets.